GRI Bio (NASDAQ:GRI – Get Free Report) and CalciMedica (NASDAQ:CALC – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.
Insider & Institutional Ownership
34.0% of GRI Bio shares are held by institutional investors. 0.9% of GRI Bio shares are held by insiders. Comparatively, 41.6% of CalciMedica shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of current recommendations and price targets for GRI Bio and CalciMedica, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| GRI Bio | 1 | 0 | 2 | 0 | 2.33 |
| CalciMedica | 1 | 0 | 1 | 0 | 2.00 |
Profitability
This table compares GRI Bio and CalciMedica’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| GRI Bio | N/A | -426.23% | -222.24% |
| CalciMedica | N/A | -270.58% | -106.45% |
Volatility and Risk
GRI Bio has a beta of -1.48, suggesting that its share price is 248% less volatile than the S&P 500. Comparatively, CalciMedica has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500.
Earnings & Valuation
This table compares GRI Bio and CalciMedica”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| GRI Bio | N/A | N/A | -$8.21 million | ($8.39) | -0.16 |
| CalciMedica | N/A | N/A | -$13.70 million | ($1.62) | -2.72 |
CalciMedica is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks.
Summary
GRI Bio beats CalciMedica on 6 of the 11 factors compared between the two stocks.
About GRI Bio
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
About CalciMedica
CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.
Receive News & Ratings for GRI Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRI Bio and related companies with MarketBeat.com's FREE daily email newsletter.
